German biopharmaceutical company Revotar has announced that its Bimosiamose inhalation solution for the treatment of COPD met its primary endpoint in a Phase 2 study involving more than 75 patients with moderate-to-severe COPD. Bimosiamose is a pan-selectin antagonist that the company is developing for asthma and acute lung injury in addition to COPD.
According to Revotar, Bimosiamose demonstrated a significant anti-inflammatory benefit, especially a reduction in Interleukin-8, compared to placebo. Patients using Bimosiamose also experienced improved lung function, with no problems tolerating the drug. Dose compliance, as measured by Activaero’s Akita Apixneb nebulizer system, was reported to be high.
Read the company’s press release.
